Global Veterinary Vaccine Market Size Likely to Surpass at a CAGR of 6.87% By 2034

As per the Veterinary Vaccine Market size analysis conducted by the CMI Team, the global Veterinary Vaccine Market is expected to record a CAGR of 6.87% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 10.06 Billion. By 2034, the valuation is anticipated to reach USD 18.29 Billion.

Overview

According to insights from industry analysts at CMI, the major companies in the Veterinary Vaccine Market are focusing on precision biotechnology, eco-friendly production, and improved cold-chain logistics. The incorporation of cutting-edge genomic technologies, AI-enabled disease surveillance, and data-driven vaccine development are revolutionizing the production and distribution of veterinary biologics. The strategic partnerships of pharmaceutical companies with research organizations and public health agencies are increasing the accessibility, effectiveness, and speed with which vaccines are developed for zoonotic disease outbreaks.

Key Trends & Drivers

• The observed increases in zoonoses and transboundary diseases, including rabies, avian influenza, and swine fever, underscore the need for preventive vaccination. The aforementioned diseases result in the deaths of large numbers of animals and trigger significant economic losses. Consequently, the need for disease prevention motivates veterinary authorities and producers to practice mast immunization aimed at safeguarding both public health and the health of the animals in their care.

• An Increase in the Attention Paid to the Health of Animals and the Safety of Food Enhancements in the safety and quality of food of animal origin, coupled with rising consumer awareness, increases food producers and farmers attention towards preventive health care. The routine use of vaccines strengthens herd productivity, reduces the need for antibiotics, and ensures the sustainability of animal husbandry and food safety.

• The veterinary application of recombinant DNA, subunit, and mRNA technologies enables unprecedented rapid and flexible design to make vaccines for multiple conditions in veterinary medicine. Genomic surveillance and deep learning models can detect and monitor emerging threats, and significantly improve preparedness for proactive vaccine development. This will greatly shorten the time required to bring new veterinary vaccines to market.

• These collaborations extend to the research and implementation phases of veterinary vaccines with the goal of enhancing the integration of early-stage research with the commercial application of veterinary vaccines. Such collaborations—coupled with a dedicated research focus on the economic aspects of veterinary vaccines fuel innovation in the development of vaccines geared for export to the market and increase the economic potential. The synergies created from these collaborations with the government have encouraged innovations in export-market veterinary vaccines. Furthermore, the economic growth of these emerging veterinary markets has increased the demand for and expanded the market for protective veterinary vaccines.

• To manage higher productivity and profitability for livestock and as a strategy to meet the rapidly growing global demand for food, particularly meat and dairy, herd immunization is becoming more common. This is in tandem with the offer of sophisticated veterinary vaccines aimed for primary pet health care demanded by a growing population of pet owners, which, together with a growing livestock population, accelerates the demand for veterinary services for animal health.

Report Scope

SWOT Analysis

• Strengths: Strong demand for Veterinary Vaccine Market stemming from preventive health care awareness, technological advancements, and well-established global distribution networks. Biotechnological and genetic engineering innovations in vaccines, along with advancements in cold-chain logistics, increase the effectiveness and accessibility of vaccines. Also, the pivotal role of the sector in the prevention of zoonoses assures sustained and universal government and institutional support.

• Weaknesses: Time sure Veterinary Vaccine Markets SWOT Analysis   The combination of high development costs, long time needed for regulatory approvals, and complex manufacturing steps act in unison to restrict the entry of smaller competitors into the market. The biological products also generate challenges because of their dependence on cold-chain storage and limited shelf life. Vaccine hesitancy among farmers, and poor awareness in low-income areas of the world, also lead to the poor uptake of vaccines and uneven coverage.

• Opportunities: Time sure Veterinary Vaccine Markets SWOT Analysis   The rapidly growing livestock industries, along with increasing pet ownership in the Asia-Pacific, Latin America, and African regions provide plentiful opportunities for capturing demand and expanding the Veterinary Vaccine Market. Next generation mRNA and DNA Veterinary Vaccines paired with digitized health records and ‘precise immunization’ will create new opportunities for profitability. The level of support from government will continue to trigger engagement to secure innovations and provide access.

• Threat: Vaccine demand and supply chains can be interrupted by erratic disease outbreaks, new viral mutations, and barriers to international trade. Increased operational risks can result from stringent regulations and burgeoning R&D costs. The presence of substitute therapies and counterfeit goods, along with poor veterinary infrastructure in some developing countries, present competition that continues to threaten long-term market growth.

List of the prominent players in the Veterinary Vaccine Market:

• Zoetis Inc.
• Boehringer Ingelheim International GmbH
• Merck & Co. Inc. (including Merck Animal Health)
• Elanco Animal Health Incorporated
• Ceva Santé Animale
• Virbac SA
• Phibro Animal Health Corporation
• HIPRA Scientific S.L.
• Hester Biosciences Limited
• Indian Immunologicals Limited
• Biogénesis Bagó S.A.
• Vaxxinova International B.V.
• Neogen Corporation
• Jinyu Bio‑technology Co. Ltd.
• Tianjin Ringpu Biotechnology Co. Ltd.
• Ourofino Saúde Animal
• LET I Pharma
• Meiji Seika Pharma Co. Ltd.
• Bayer Animal Health (now part of Elanco)
• Dechra Pharmaceuticals PLC
• Others